...
首页> 外文期刊>Journal of Biomolecular Structure and Dynamics >Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease
【24h】

Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease

机译:鉴定潜在的PKC抑制剂,通过药程学设计,3D-QSAR和靶向阿尔茨海默病的分子动力学模拟

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Protein kinases are ubiquitously expressed as Serine/Threonine kinases, and play a crucial role in cellular activities. Protein kinases have evolved through stringent regulation mechanisms. Protein kinases are also involved in tauopathy, thus are important targets for developing Anti-Alzheimer's disease compounds. Structures with an indole scaffold turned out to be potent new leads. With the aim of developing new inhibitors for human protein kinase C, here we report the generation of four point 3D geometric featured pharmacophore model. In order to identify novel and potent PKC6 inhibitors, the pharmacophore model was screened against 80,000,00 compounds from various chemical databases such as., ZINC, SPEC, ASINEX, which resulted in 127 compound hits, and were taken for molecular docking filters (HTVS, XP docking). After in-depth analysis of binding patterns, induced fit docking (flexible) was employed for six compounds along with the cocrystallized inhibitor. Molecular docking study reveals that compound 6F found to be tight binder at the active site of PKC6 as compared to the cocrystal and has occupancy of 90 percentile. MM-GBSA also confirmed the potency of the compound 6F as better than cocrystal. Molecular dynamics results suggest that compound 6F showed good binding stability of active sites residues similar to cocrystal 7G compound. Present study corroborates the pharma-cophore-based virtual screening, and finds the compound 6F as a potent Inhibitor of PKC, having therapeutic potential for Alzheimer's disease. Worldwide, 46.8 million people are believed to be living with Alzheimer's disease. When elderly population increases rapidly and neurodegenerative burden also increases in parallel, we project the findings from this study will be useful for drug developing efforts targeting Alzheimer's disease.
机译:蛋白激酶普遍地表达为丝氨酸/苏氨酸激酶,并在细胞活性发挥至关重要的作用。蛋白质激酶通过严格的调节机制演变。蛋白激酶也参与施坦病,因此是抗阿尔茨海默病化合物的重要靶标。带有吲哚脚手架的结构原来是有效的新引线。目的是开发人蛋白激酶C的新抑制剂,在这里,我们报告了四点3D几何特色药物电影模型的产生。为了鉴定新颖和有效的PKC6抑制剂,将药物模型从各种化学数据库中的80,000,00化合物筛选,例如。,锌,规格,asinex,导致127个化合物击中,并用于分子对接过滤器(HTV ,XP对接)。在深入分析结合图案之后,使用诱导的配合对接(柔性)与共聚抑制剂一起使用六种化合物。分子对接研究表明,与COCRYSTAL相比,在PKC6的活性位点处发现的化合物6F是紧密粘合剂,并且占用90百分位数。 MM-GBSA还证实了化合物6F的效力,如钴。分子动力学结果表明,化合物6F显示出类似于Cocrystal 7g化合物的活性位点残基的良好结合稳定性。目前的研究证实了基于Pharmo-Cophore的虚拟筛选,并将化合物6F作为PKC的有效抑制剂,具有阿尔茨海默病的治疗潜力。在全球范围内,4680万人被​​认为与阿尔茨海默病有关。当老年人口迅速增加而神经变性负担也平行增加时,我们从本研究中项目的调查结果将有助于针对阿尔茨海默病的努力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号